Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35387563)

  • 1. Fraxetin down-regulates polo-like kinase 4 (PLK4) to inhibit proliferation, migration and invasion of prostate cancer cells through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway.
    Ma Z; Sun Y; Peng W
    Bioengineered; 2022 Apr; 13(4):9345-9356. PubMed ID: 35387563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
    Xu B; Li J; Xu D; Ran Q
    Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fraxetin inhibits proliferation and induces apoptosis of bladder cancer through the Akt pathway in vitro and in vivo.
    Weng M; Deng Z; Huang S; Lin X; Xu N; Sun X; Wu W; Lu J; Wang D
    J Biochem Mol Toxicol; 2024 Jan; 38(1):e23556. PubMed ID: 37867445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21.
    Zhu G; Liu X; Li H; Yan Y; Hong X; Lin Z
    Int J Immunopathol Pharmacol; 2018; 32():2058738418814341. PubMed ID: 30477356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fraxetin suppresses reactive oxygen species-dependent autophagy by the PI3K/Akt pathway to inhibit isoflurane-induced neurotoxicity in hippocampal neuronal cells.
    Zhang T; Zhou B; Sun J; Song J; Nie L; Zhu K
    J Appl Toxicol; 2022 Apr; 42(4):617-628. PubMed ID: 34553399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Picropodophyllin Inhibits the Proliferation of Human Prostate Cancer DU145 and LNCaP Cells via ROS Production and PI3K/AKT Pathway Inhibition.
    Zhu X; Chen X; Wang G; Lei D; Chen X; Lin K; Li M; Lin H; Li D; Zheng Q
    Biol Pharm Bull; 2022; 45(8):1027-1035. PubMed ID: 35908886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
    Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sinodielide A exerts thermosensitizing effects and induces apoptosis and G2/M cell cycle arrest in DU145 human prostate cancer cells via the Ras/Raf/MAPK and PI3K/Akt signaling pathways.
    Hatashita M; Taniguchi M; Baba K; Koshiba K; Sato T; Jujo Y; Suzuki R; Hayashi S
    Int J Mol Med; 2014 Feb; 33(2):406-14. PubMed ID: 24285252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
    Cai F; Zhang Y; Li J; Huang S; Gao R
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Crypotanshione reduces the expression of metadherin in DU145 prostate cancer cells].
    Yao Y; Li HZ; Qian BJ; Liu CM; Zhang JB; Lin MC
    Zhonghua Nan Ke Xue; 2015 Sep; 21(9):782-7. PubMed ID: 26552209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
    Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
    Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircLMTK2 acts as a tumor suppressor in prostate cancer via regulating the expression of microRNA-183.
    Jin C; Zhao W; Zhang Z; Liu W
    Life Sci; 2020 Jan; 241():117097. PubMed ID: 31760099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 16. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breviscapine suppresses the growth and metastasis of prostate cancer through regulating PAQR4-mediated PI3K/Akt pathway.
    Ye J; Gao M; Guo X; Zhang H; Jiang F
    Biomed Pharmacother; 2020 Jul; 127():110223. PubMed ID: 32413672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
    Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
    Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.